Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard Robin sold 429 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $35.85, for a total transaction of $15,379.65. Following the completion of the sale, the chief executive officer directly owned 54,198 shares of the company’s stock, valued at $1,942,998.30. This represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Nektar Therapeutics Stock Down 7.2%
Shares of NKTR opened at $30.20 on Friday. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -4.67 and a beta of 1.44. The company’s fifty day moving average is $44.60 and its 200-day moving average is $64.46. Nektar Therapeutics has a 12 month low of $30.13 and a 12 month high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.07) by $0.44. The business had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.27 million. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. As a group, research analysts predict that Nektar Therapeutics will post -7.39 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. Canaccord Genuity Group cut their target price on Nektar Therapeutics from $153.00 to $149.00 and set a “buy” rating on the stock in a report on Monday, November 16th. Raymond James Financial started coverage on Nektar Therapeutics in a research report on Friday, October 9th. They issued a “market perform” rating for the company. UBS Group assumed coverage on Nektar Therapeutics in a research note on Monday, October 12th. They set a “neutral” rating and a $53.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Friday, August 28th. Finally, HC Wainwright reissued a “buy” rating and set a $185.00 price objective on shares of Nektar Therapeutics in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $130.33.
Check Out Our Latest Stock Report on NKTR
Institutional Trading of Nektar Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Two Seas Capital LP grew its stake in Nektar Therapeutics by 8.2% in the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock valued at $202,582,000 after buying an additional 253,744 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Nektar Therapeutics by 171.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company’s stock worth $37,614,000 after acquiring an additional 392,759 shares during the period. Braidwell LP raised its holdings in Nektar Therapeutics by 112.7% in the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock worth $33,063,000 after acquiring an additional 250,916 shares during the period. Orbimed Advisors LLC bought a new position in Nektar Therapeutics in the 1st quarter worth $19,786,000. Finally, ADAR1 Capital Management LLC lifted its position in Nektar Therapeutics by 123.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 161,252 shares of the biopharmaceutical company’s stock worth $11,602,000 after acquiring an additional 89,221 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Featured Articles
- Five stocks we like better than Nektar Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
